The Drug Enforcement Administration will be subject to new deadlines and requirements for scheduling new drugs and for approving applications related to clinical trials, under a bill signed into law by President Obama Nov. 25. The Improving Regulatory Transparency for New Medical Therapies Act (H.R. 639) aims to ensure that DEA schedules newly approved drugs in a timely manner, br... Read More